"Cancer of the China Miracle" attention

Swedish Karolinska Institute of Cell and Gene Therapy Center Coordinator Prof. Dr. Dilber Sirac, "Cancer of the China Miracle" is identified as a large number of drugs for treatment in Turkey and Europe are going to China by the patient, the patient was alert.

Dilber, based on the p53 gene in European and American pharmaceutical drugs to be sold in the market currently is not authorized by the agency said.

Dilber Sirac, "cancer miracle in China" launched as a drug, the body guards of the gene known as p53'u based and healthy cells in the p53 gene by adding a simple virus, the cancer cells are made by injection. This method has not been discovered in China and known for years that the phrase Dilber, drugs produced by this method, with many parts of the world created in laboratory conditions was point.

Almost identical to that shown as miracle drugs in the United States since 1994 by a company is subject to various research and clinical studies on head-neck cancer using language which has been begun Dilber, şöyle devam etti:

"This continues to be the company's Phase 3 clinical studies. The results of this clinical study full does not occur, and the head-neck cancer has an impact not conclude whether the European Medicines Agency (EMEA) and the U.S. Drug Agency (FDA) to be sold in the market is currently not allowed. "

CHINA MEDICINE CORPORATION PERMISSION of

America and Europe and in the ethics of drug control is very strict because of the many companies in the Far East countries, said the lead Dilber that in 2003, a researcher is a partner of the firm's China in Drug Authority (SFDA) of the drug only top-neck tumors to be used in the clinical record is used in the permit that was saved. Dilber, SFDA'nın also in 2004 that drug use in the head-neck tumors decided to sell the record in the market said.
Creation science circles that decision SFDA'nın söyleyen astonishment Dilber, especially in the case of commercial concerns about the medication has made many problematical. SFDA'nın decision after the company's drug of first gene therapy medicine as "that indicates market Dilber, then things are even more off the rails, Europe and America, many institutions and associations, companies like be on the scientific data has been announced. The company's international success of any therapeutic yayınlayamadığını on the magazine said the Dilber, thus further increasing their doubts about the drugs you are defending.

Dilber, 2005 are included in some statistical results, the Chinese researchers in an article that said information is not held each other and are determined some distortion of information, is published in a magazine reported.

WARNING in China for treatment

Chinese patients' treatment by the government to meet the demand for "drug effect is not certain" that has been rejected highlight Dilber, Turkey and Europe, some companies and people who abuse this business in China by various health organizations who want to understand every cancer patient for treatment was taken to China was recorded.

Head-neck in China, only licensed for tumors of the drug for a patient of the total price of 3 thousand 360 dollars that emphasize Dilber, but going to China, the cost of treatment for patients is about 50 thousand - 60 thousand dollars has been mentioned as a defense of the patient was alert.

Dilber, not yet completed studies of medicine, resulting in children with growth disorders may cause added words.